Search Results for: "Recovery"

This post has been archived and contains information that may be out of date.

The California Department of Public Health has released All Facilities Letter (AFL) 19-02.1, which rescinds AFL 19-02 and further clarifies licensing requirements related to treatment for narcotic addiction.

This post has been archived and contains information that may be out of date.

In an effort to help reduce the stigma around behavioral health issues, CHA has released a new video featuring five accomplished health care executives who have faced mental health challenges. The powerful “truth telling” video is the product of the keynote session at CHA’s recent Behavioral Health Symposium. 

This post has been archived and contains information that may be out of date.

The Centers for Medicare & Medicaid Services (CMS) yesterday released its final rule updating the Medicare physician fee schedule (PFS) and other Medicare Part B payment policies for calendar year (CY) 2019. The final rule includes a number of significant proposals that will impact hospitals and clinicians. Included in the PFS final rule is an interim final rule that implements provisions of the recently signed Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.

This post has been archived and contains information that may be out of date.

Earlier this month, the Centers for Medicare & Medicaid Services (CMS) issued the attached proposed rule updating Medicare Advantage and the Part D prescription drug program for contract year 2019. Among the proposed changes, CMS would codify the current Quality Star Rating System for Medicare Advantage and Part D plans, eliminate the “meaningfully different” standard that Medicare Advantage organizations must meet if they offer multiple plans in the same county and change the open enrollment period to Jan. 1 through March 31.

CMS also solicits comments on how Part D plan sponsors — through their pharmacy benefit managers — negotiate drug price concessions from drug manufacturers, network pharmacies and other entities. Specifically, CMS is interested in learning if Part D plans and their pharmacy benefit managers are lowering premiums and cost-sharing for beneficiaries because of the savings generated from price concessions.

This post has been archived and contains information that may be out of date.

CHA has submitted the attached comments to the Office of Medicare Hearings and Appeals (OMHA), responding to its request for information (RFI) on initiatives to address the current backlog of claims pending at the administrative law judge (ALJ) level of appeals. While CHA applauds OMHA’s willingness to begin to address the backlog through a number of pilot programs, the increase in recovery audit contractor (RAC) claim denials will intensify challenges at the ALJ level without fundamental RAC reform. CHA urges OMHA to improve the transparency of data by continuing to release it on a quarterly basis and including additional information, such as the total number of claims, total charges being appealed by the individual Medicare payment system, the most frequent reason for appeals, the number of requests overturned on appeal and the number of cases that moved to the ALJ level. CHA also urges OMHA to improve communication on its established pilots, such as hosting a provider call to educate hospitals on the methodology of its statistical sampling pilot.

This post has been archived and contains information that may be out of date.

CHA sent a letter this week to the Centers for Medicare & Medicaid Services (CMS) voicing concerns regarding a CMS proposed rule on patient notification.